Suppr超能文献

前列腺癌筛查:更新多个系统评价以提供信息,为加拿大预防保健工作组指南更新服务的方案。

Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update.

机构信息

School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Department of Family Medicine, McGill University, Montreal, Quebec, Canada.

出版信息

Syst Rev. 2022 Oct 26;11(1):230. doi: 10.1186/s13643-022-02099-9.

Abstract

PURPOSE

To inform updated recommendations by the Canadian Task Force on Preventive Health Care on screening for prostate cancer in adults aged 18 years and older in primary care. This protocol outlines the planned scope and methods for a series of systematic reviews.

METHODS

Updates of two systematic reviews and a de novo review will be conducted to synthesize the evidence on the benefits and harms of screening for prostate cancer with a prostate-specific antigen (PSA) and/or digital rectal examination (DRE) (with or without additional information) and patient values and preferences. Outcomes for the benefits of screening include reduced prostate cancer mortality, all-cause mortality, and incidence of metastatic prostate cancer. Outcomes for the harms of screening include false-positive screening tests, overdiagnosis, complications due to biopsy, and complications of treatment including incontinence (urinary or bowel), and erectile dysfunction. The quality of life or functioning (overall and disease-specific) and psychological effects outcomes are considered as a possible benefit or harm. Outcomes for the values and preferences review include quantitative or qualitative information regarding the choice to screen or intention to undergo screening. For the reviews on benefits or harms, we will search for randomized controlled trials, quasi-randomized, and controlled studies in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials. For the review on values and preferences, we will search for experimental or observational studies in MEDLINE, Embase, and PsycInfo. For all reviews, we will also search websites of relevant organizations, gray literature, and reference lists of included studies. Title and abstract screening, full-text review, data extraction, and risk of bias assessments will be completed independently by pairs of reviewers with any disagreements resolved by consensus or by consulting with a third reviewer. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach will be used to assess the certainty of the evidence for each outcome.

DISCUSSION

The series of systematic reviews will be used by the Canadian Task Force on Preventive Health Care to update their 2014 guideline on screening for prostate cancer in adults aged 18 years and older. Systematic review registration This review has been registered with PROSPERO (CRD42022314407) and is available on the Open Science Framework (osf.io/dm32k).

摘要

目的

为了向加拿大预防保健工作组通报最新建议,即在初级保健中对 18 岁及以上成年人进行前列腺癌筛查。本方案概述了一系列系统评价的计划范围和方法。

方法

将对两项系统评价和一项全新的评价进行更新,以综合有关使用前列腺特异性抗原(PSA)和/或直肠指检(DRE)(有或无额外信息)进行前列腺癌筛查的益处和危害以及患者价值观和偏好的证据。筛查益处的结局包括前列腺癌死亡率、全因死亡率和转移性前列腺癌的发病率降低。筛查危害的结局包括假阳性筛查试验、过度诊断、活检相关并发症以及包括尿失禁(尿便失禁)和勃起功能障碍在内的治疗相关并发症。生活质量或功能(整体和疾病特异性)和心理影响结局被视为可能的益处或危害。价值观和偏好评价的结局包括有关筛查选择或进行筛查意愿的定量或定性信息。对于益处或危害评价,我们将在 MEDLINE、Embase 和 Cochrane 对照试验中心注册库中搜索随机对照试验、准随机和对照研究。对于价值观和偏好评价,我们将在 MEDLINE、Embase 和 PsycInfo 中搜索实验或观察性研究。对于所有评价,我们还将在相关组织的网站、灰色文献和纳入研究的参考文献中进行搜索。标题和摘要筛选、全文审查、数据提取和偏倚风险评估将由 pairs of reviewers 独立完成,任何分歧将通过共识或咨询第三位审稿人解决。将使用 GRADE(推荐评估、制定与评价)方法对每个结局的证据确定性进行评估。

讨论

该系列系统评价将由加拿大预防保健工作组用于更新其 2014 年关于 18 岁及以上成年人前列腺癌筛查的指南。系统评价注册 本评价已在 PROSPERO(CRD42022314407)上注册,并可在 Open Science Framework(osf.io/dm32k)上获得。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7457/9609189/b6a3efdcdf56/13643_2022_2099_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验